UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment

Journal of medicinal chemistry, 2015-02, Vol.58 (3), p.1038-1052

2015

Volltextzugriff (PDF)

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Nature communications, 2021-05, Vol.12 (1), p.2621-2621, Article 2621

2021

Volltextzugriff (PDF)

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

Journal of medicinal chemistry, 2013-07, Vol.56 (13), p.5553-5561

2013

Volltextzugriff (PDF)

High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction

Journal of the American Chemical Society, 2013-01, Vol.135 (2), p.669-682

2013

Volltextzugriff (PDF)

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

Nature communications, 2017-10, Vol.8 (1), p.1150-12, Article 1150

2017

Volltextzugriff (PDF)

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein–Protein Interaction

Journal of medicinal chemistry, 2018-03, Vol.61 (5), p.1934-1950

2018

Volltextzugriff (PDF)

Activating STAT6 mutations in follicular lymphoma

Blood, 2015-01, Vol.125 (4), p.668-679

2015

Volltextzugriff (PDF)

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction

Journal of medicinal chemistry, 2017-06, Vol.60 (12), p.4818-4839

2017

Volltextzugriff (PDF)

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Proceedings of the National Academy of Sciences - PNAS, 2008-03, Vol.105 (10), p.3933-3938

2008

Volltextzugriff (PDF)

Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Protein–Protein Interaction

Journal of medicinal chemistry, 2013-02, Vol.56 (3), p.1113-1123

2013

Volltextzugriff (PDF)

Small molecules block the interaction between porcine reproductive and respiratory syndrome virus and CD163 receptor and the infection of pig cells

Virology journal, 2020-07, Vol.17 (1), p.1-116, Article 116

2020

Volltextzugriff (PDF)

Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma

Clinical cancer research, 2016-11, Vol.22 (21), p.5383-5393

2016

Volltextzugriff (PDF)

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Molecular cancer therapeutics, 2008-06, Vol.7 (6), p.1533-1542

2008

Volltextzugriff (PDF)

Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions

The Journal of biological chemistry, 2010-07, Vol.285 (27), p.21023-21036

2010

Volltextzugriff (PDF)

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges

Cold Spring Harbor perspectives in medicine, 2017-05, Vol.7 (5), p.a026245

2017

Volltextzugriff (PDF)

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Protein-Protein Interactions, 2012, p.57-79

2012

Volltextzugriff (PDF)

Discovery of 4‑((3′R,4′S,5′R)‑6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Journal of medicinal chemistry, 2017-04, Vol.60 (7), p.2819-2839

2017

Volltextzugriff (PDF)

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (20), p.5855-5865

2014

Volltextzugriff (PDF)

Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors

Journal of the American Chemical Society, 2013-05, Vol.135 (19), p.7223-7234

2013

Volltextzugriff (PDF)

AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development

Journal of medicinal chemistry, 2012-06, Vol.55 (11), p.4934-4935

2012

Volltextzugriff (PDF)

Identification of New Compounds against PRRSV Infection by Directly Targeting CD163

Journal of virology, 2023-05, Vol.97 (5), p.e0005423-e0005423

2023

Volltextzugriff (PDF)

Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics

Biodiscovery, 2013-06, Vol.8 (8), p.4-15

2013

Volltextzugriff (PDF)

Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation

Clinical cancer research, 2021-04, Vol.27 (8), p.2301-2313

2021

Volltextzugriff (PDF)

Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles

Journal of medicinal chemistry, 2014-12, Vol.57 (24), p.10486-10498

2014

Volltextzugriff (PDF)

Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction

Angewandte Chemie (International ed.), 2018-02, Vol.57 (6), p.1601-1605

International ed. in English, 2018

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(69)
Japanisch
(14)
Deutsch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein–Protein Interaction

Activating STAT6 mutations in follicular lymphoma

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Protein–Protein Interaction

Small molecules block the interaction between porcine reproductive and respiratory syndrome virus and CD163 receptor and the infection of pig cells

Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression

Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors

AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development

Identification of New Compounds against PRRSV Infection by Directly Targeting CD163

Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics

Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation

Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles

Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction

Suchergebnisse filtern